论文部分内容阅读
目的探讨胃癌组织中KAI1/CD82、ME491/CD63的表达及与临床病理的关系。方法应用免疫组化SABC法,检测63例胃癌组织中KAI1/CD82、ME491/CD63的表达,比较其与临床病理的关系。结果无淋巴结转移,病理分化Ⅰ、Ⅱ级,癌组织面积小的胃癌组织KAI1/CD82阳性表达率高于有淋巴结转移、病理分化Ⅲ级、癌组织面积大者,差异有统计学意义(P<0.05);ME491/CD63表达与有无淋巴结转移、病理分级程度、浸润深度、癌组织面积大小,差异无统计学意义。结论 KAI1/CD82可作为胃癌的预后指标。
Objective To investigate the expression of KAI1 / CD82, ME491 / CD63 in gastric cancer and its relationship with clinicopathology. Methods The expression of KAI1 / CD82 and ME491 / CD63 in 63 cases of gastric carcinoma was detected by immunohistochemical SABC method. The relationship between KAI1 / CD82 and ME491 / CD63 was compared with clinicopathological parameters. Results The positive rate of KAI1 / CD82 in gastric cancer tissues without lymph node metastasis, grade Ⅰ and Ⅱ, and with small area of cancerous tissue was higher than that with lymph node metastasis, pathological grade Ⅲ and large area of cancerous tissue (P < 0.05). There was no significant difference in the expression of ME491 / CD63 with or without lymph node metastasis, the degree of pathological grading, the depth of invasion, the size of the cancerous tissue. Conclusion KAI1 / CD82 can be used as a prognostic indicator of gastric cancer.